The launch of tirzepatida in Ecuador introduces the first dual GIP and GLP-1 receptor agonist to combat the country’s escalating obesity crisis, offering new hope for metabolic disease management.
Tirzepatida is now available in Ecuador as a new prescription option for people with type 2 diabetes, overweight and obesity, after approval by the country’s National Agency for Regulation, Control and Sanitary Surveillance, known as ARCSA. According to El Diario, it is the first dual GIP and GLP-1 receptor agonist to reach the Ecuadorian market, adding to the limited set of medicines doctors can use against metabolic disease.
The launch comes as excess weight continues to rise sharply across the region. El Diario, citing Pan American Health Organization data, said more than 63.6% of adults in Ecuador have excess weight, while the share of people affected across the Americas climbed from 44.4% in 1990 to 67.5% in 2022 and could reach 73.2% by 2030. That trend has intensified pressure on health systems because obesity is closely linked to type 2 diabetes, cardiovascular disease and other long-term conditions.
Medical reviews hosted by the U.S. National Library of Medicine help explain why tirzepatida has drawn attention. The drug works by activating both GIP and GLP-1 receptors, two incretin pathways involved in insulin release, appetite control and blood-sugar regulation. Studies and review articles say that dual action can improve glucose control, slow stomach emptying and increase satiety, which is why the medicine is used in the treatment of diabetes and weight-related disease.
Even so, the drug is not a stand-alone solution. El Diario said tirzepatida must be prescribed by a doctor and used alongside diet and exercise, rather than replacing them. In practice, that means clinicians must judge whether it is suitable for each patient individually, especially where obesity is accompanied by high blood pressure, raised cholesterol, prediabetes, sleep apnoea or established heart disease.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
